Last reviewed 2026-05-19 · How we verify

PAVBLU (AFLIBERCEPT-AYYH)

AMGEN INC · FDA-approved approved ✓ Verified May 2026 Quality 6/100

PAVBLU (generic name: AFLIBERCEPT-AYYH) is a Vascular Endothelial Growth Factor Inhibitor [EPC] drug developed by AMGEN INC. It is currently FDA-approved.

ABP 938 is a vascular endothelial growth factor A inhibitor, a type of protein modality drug. It is being studied in combination with aflibercept (Eylea) for the treatment of chorioretinal vascular disease.

At a glance

Generic name	AFLIBERCEPT-AYYH
Sponsor	AMGEN INC
Drug class	Vascular Endothelial Growth Factor Inhibitor [EPC]
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

Conjunctival hemorrhage
Eye pain
Cataract
Vitreous detachment
Vitreous floaters
Intraocular pressure increased

Serious adverse events

Endophthalmitis
Retinal detachment
Retinal vasculitis
Occlusive retinal vasculitis
Hypersensitivity
Retinal tear
Corneal edema
Injection site hemorrhage

Key clinical trials

An Open Label, Two-Arm Study in Subjects With Chorioretinal Vascular Disease to Evaluate ABP 938 and Aflibercept (Eylea®) in a Prefilled Syringe (Phase 3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PAVBLU CI brief — competitive landscape report
PAVBLU updates RSS · CI watch RSS
AMGEN INC portfolio CI

Frequently asked questions about PAVBLU

What is PAVBLU?

PAVBLU (AFLIBERCEPT-AYYH) is a Vascular Endothelial Growth Factor Inhibitor [EPC] drug developed by AMGEN INC.

Who makes PAVBLU?

PAVBLU is developed and marketed by AMGEN INC (see full AMGEN INC pipeline at /company/amgen).

What is the generic name of PAVBLU?

AFLIBERCEPT-AYYH is the generic (nonproprietary) name of PAVBLU.

What drug class is PAVBLU in?

PAVBLU belongs to the Vascular Endothelial Growth Factor Inhibitor [EPC] class. See all Vascular Endothelial Growth Factor Inhibitor [EPC] drugs at /class/vascular-endothelial-growth-factor-inhibitor-epc.

What development phase is PAVBLU in?

PAVBLU is FDA-approved (marketed).

What are the side effects of PAVBLU?

Common side effects of PAVBLU include Conjunctival hemorrhage, Eye pain, Cataract, Vitreous detachment, Vitreous floaters, Intraocular pressure increased. Serious adverse events: Endophthalmitis, Retinal detachment, Retinal vasculitis, Occlusive retinal vasculitis.

Drug class: All Vascular Endothelial Growth Factor Inhibitor [EPC] drugs
Manufacturer: AMGEN INC — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing